Ironwood Pharmaceuticals (IRWD) Expected Earnings Growth: Is It Worth Buying?

The market expects Ironwood Pharmaceuticals (IRWD) to report year-over-year earnings for the quarter ended December 2022, with lower revenues. This well-known consensus outlook is important when assessing a company’s earnings picture, but the most important factor that can impact a company’s near-term share price is how actual results compare to estimates.

Shares could move higher if these key numbers meet expectations in the upcoming earnings report, due on February 16. On the other hand, if these key numbers are not met, the stock could fall.

While the sustainability of the immediate price movement and future earnings expectations will largely depend on management’s discussion of business conditions during the earnings call, it is worth limiting the likelihood of a positive EPS surprise.

Zacks Consensus Estimate

The drugmaker is expected to post quarterly earnings per share of $0.29 per share in its upcoming report, representing a year-over-year change of +7.4%.

Revenue is expected to be $113.28 million, down 3.3% from the year-ago quarter.

Estimate the trend of change

The consensus EPS estimate for the quarter has not changed over the last 30 days. This broadly reflects how analysts covering the data have collectively re-evaluated their initial estimates during this period.

Investors should note that the aggregate change does not necessarily reflect the direction of estimate revisions by each major analyst.

Whisper about earnings

Revisions to estimates prior to a company’s earnings release provide an indication of business conditions in the period in which the earnings are expected to be released. This insight is at the heart of our proprietary surprise prediction model, the Zacks Earnings ESP.

The Zacks Earnings ESP compares the Most Accurate Estimates to the Zacks Consensus Estimates for the quarter; The Most Accurate Estimate is a newer revision of the Zacks Consensus EPS estimate. The idea is that analysts reviewing their estimates just before an earnings release have the latest information that could potentially be more accurate than what they and other consensus participants had previously predicted.

Thus, a positive or negative ESP reading theoretically indicates the likely deviation of actual earnings from consensus estimates. However, the predictive power of the model is only significant for positive ESP readings.

A positive Earnings ESP is a strong predictor of an earnings beat, especially when paired with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks in this combination deliver a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of its Earnings ESP.

Please note that a negative earnings ESP reading does not mean a loss of earnings. Our research shows that it is difficult to predict earnings growth with any degree of confidence for stocks with negative ESP readings and/or a Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How have the numbers changed at Ironwood?

For Ironwood, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company’s earnings prospects. This resulted in an earnings ESP of -2.30%.

On the other hand, the stock currently sports a Zacks Rank of #4.

So this combination makes it difficult to confidently predict that Ironwood will beat the consensus EPS estimate.

Does the history of surprising results have any clue?

When calculating future earnings estimates, analysts often consider how well a company has been able to match consensus estimates in the past. So it’s worth taking a look at the surprise history to gauge its impact on the upcoming issue.

For the last reported quarter, Ironwood was expected to post earnings of $0.27 per share when it actually produced earnings of $0.28, representing a surprise of +3.70%.

Over the last four quarters, the company has surpassed consensus EPS estimates only once.

Bottom line

Improving or lacking earnings may not be the only basis for a stock’s value rising or falling. Many stocks lose value despite good earnings because of other factors that disappoint investors. Similarly, unforeseen catalysts help many stocks gain despite losing profits.

That said, betting on stocks that are expected to exceed earnings expectations increases your chances of success. Therefore, it is worth checking the company’s Earnings Rank and Zacks Rank before their quarterly release. Use our Earnings ESP filter to find the best stocks to buy or sell before they report.

Ironwood doesn’t seem like a compelling candidate to beat earnings. However, investors should also pay attention to other factors if they want to bet on or stay away from these stocks ahead of an earnings release.

Expected results of an industry player

Karyopharm Therapeutics (KPTI), another stock belonging to the Zacks Medical – Drugs industry, is expected to post earnings per share of $0.34 for the quarter ended December 2022. These estimates indicate a year-over-year change of -173.9%. Revenue for the quarter is expected to be $33.88 million, down 73.2% from the same quarter last year.

The consensus EPS estimate for Karyopharm Therapeutics has been revised 2.6% down to the current level over the last 30 days. However, the lower value of the most accurate estimate resulted in an earnings ESP of -0.92%.

Combined with a Zacks Rank #3 (Hold), the earnings ESP makes it difficult to confidently predict that Karyopharm Therapeutics will surpass consensus EPS estimates. The company has beaten consensus EPS estimates in each of the four consecutive quarters.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

Want the latest recommendations from Zacks Investment Research? Today you can download the top 7 stocks for the next 30 days. Click to get this free report

Ironwood Pharmaceuticals, Inc. (IRWD): Free Inventory Analysis Report

Karyopharm Therapeutics Inc. (KPTI): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research